Dogs in the standard - dose and low - dose
pimobendan groups had significantly longer median survival times than dogs in the conventional group (334, 277 and 136 days, respectively; P < 0.001).
In the EPIC Study, dogs in
the pimobendan group experienced 10 % more life without congestive heart failure (CHF) signs that impact quality of life (10 % more life without CHF was calculated based on an estimated lifespan for all small to medium ‑ sized dogs being 12.5 years.
Median time to composite primary endpoint was 1228 days in
the pimobendan group and 766 days in the placebo group (P = 0.0038).
In the EPIC Study, dogs in
the pimobendan group experienced 60 % more time in asymptomatic stage B2 of heart disease and 10 % more life without CHF signs that impact quality of life (10 % more life without CHF was calculated based on an estimated lifespan for all small to medium ‑ sized dogs being 12.5 years.
Not exact matches
In a study of Doberman Pinschers, 80 % of the dogs treated with
pimobendan showed improvements in the quality ‑ of ‑ life measures (including exercise tolerance, coughing, dyspnea, and fatigue) compared with only 10 % in the
group not treated with
pimobendan.7
The 360 canine patients enrolled in the trial randomly received
pimobendan or a placebo, with 180 dogs in each
group.